Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines
Cecilia Garofalo(Istituto Ortopedico Rizzoli), Katia Scotlandi(Istituto Ortopedico Rizzoli)
Cited by 37
Related Papers
Preclinical <i>In vivo</i> Study of New Insulin-Like Growth Factor-I Receptor–Specific Inhibitor in Ewing's Sarcoma
|Clinical Cancer Research|2007|133
Contribution of MEK/MAPK and PI3‐K signaling pathway to the malignant behavior of Ewing's sarcoma cells: Therapeutic prospects
|International Journal of Cancer|2003|66
Metformin as an Adjuvant Drug against Pediatric Sarcomas: Hypoxia Limits Therapeutic Effects of the Drug
|PLoS ONE|2013|47